● By searching treatments, the pharmaceutical industry is increasing the chances of emerging from the humanitarian crisis as soon as possible.
August 2020 – While the search for the vaccine relentlessly continues, the industry has decided to increase the chances of ending the coronavirus crisis by seeking treatments for patients with the virus. Through research and partnerships, the pharmaceutical industry is testing the effectiveness of existing medicines and searching for new ones. This titanic quest in such a short time has proven the industry’s commitment to the whole world.
Thanks to partnerships, collaboration and research, the development of treatments is moving swiftly. This commitment to find medicine for treating the disease increases the chances of coming out of the humanitarian crisis soon.
To answer all questions about the status of COVID-19 treatments, this Thursday, August 13 at 11:00 am EST (Miami), the Latin American Federation of the Pharmaceutical Industry (FIFARMA), will hold a briefing with the participation of pharmaceutical companies such as Novartis, MSD and Roche, which are in the search of treatments for coronavirus patients.
With all eyes on the vaccine, it is necessary to put on the table information on treatments that could be a possible solution to coronavirus disease. Currently, there are clinical trials conducted in 21 countries worldwide, in order to speed up the search for a drug. All trials rely on medicines formerly developed by the pharmaceutical industry for other purposes during a long history in innovation and development.
Research is then the key to success for the recovery of those patients entering the most critical phases of the disease. Through clinical trials, the industry has evaluated the effectiveness and safety of some medicines, always providing not to disrupt the distribution chains of other necessary medicines.
For example, platforms have been created for trials such as Solidarity, led by the World Health Organization, or Recovery, led by the United Kingdom; companies from the industry are concurrently performing their own trials with different treatments. This level of collaboration and mobilization has demonstrated a robust biopharmaceutical ecosystem, working closely with governments and organizations to ensure accessibility and availability of treatments.
Collaboration in research is also necessary to face the vast possibilities in the field of treatments. Antiviral treatments are currently being researched, which work by preventing the virus from replicating or infecting cells; antibody treatments, which are based on cured patients’ antibodies and manage to block the proteins that coronavirus uses to infect human cells; and blood plasma from recovered patients, which may contain antibodies against infection.
There are also indirect therapies that do not treat or prevent the virus directly, but help infected patients mitigating the effects of the disease. This type of treatments leverages the immune system of the most severe hospitalized patients.
During the virtual event, industry experts will answer questions about the medicines currently tested for coronavirus, the partnerships being made to accelerate research and discovery processes, manufacturing challenges and supply chains, and the lessons for the industry in this process.
The experts who will join us in this COVID-19 treatments session will be Dr. Carlos Garay, Novartis Vice President and Regional Head of Oncology for Latin America and Canada, Dr. Daniel Ciriano, Roche Medical Affairs Competency Lead, Dr. Fabiane El-Far, MSD Executive Director, Medical Affairs Vaccines and Infectious Diseases for Latin America, and Rafael Andrés Díaz-Granados, FIFARMA Executive Director. The panel will be moderated by Dr. Fernanda Hernández, physician and presenter in Noticias Caracol (Colombia).
This is an event for journalists. Those interested in participating with questions should register in this link to access the event, mentioning the media they represent.
The Latin American Federation of the Pharmaceutical Industry (FIFARMA) represents 14 research-based biopharmaceutical companies and 11 local associations engages in discovering and developing innovative health products and services that improve the quality of life of patients in Latin America and the Caribbean. The Federation advocates for patient-centric, sustainable healthcare systems characterized by high regulatory standards and ethical principles.